Abbott Laboratories (NYSE:ABT) Shares Bought by Trust Co. of Toledo NA OH

Trust Co. of Toledo NA OH lifted its holdings in shares of Abbott Laboratories (NYSE:ABT) by 0.2% during the fourth quarter, Holdings Channel.com reports. The fund owned 72,859 shares of the healthcare product maker’s stock after acquiring an additional 136 shares during the period. Abbott Laboratories accounts for approximately 1.1% of Trust Co. of Toledo NA OH’s holdings, making the stock its 18th biggest holding. Trust Co. of Toledo NA OH’s holdings in Abbott Laboratories were worth $8,241,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently modified their holdings of the stock. Fiduciary Alliance LLC raised its holdings in shares of Abbott Laboratories by 145.6% in the fourth quarter. Fiduciary Alliance LLC now owns 17,936 shares of the healthcare product maker’s stock worth $2,029,000 after buying an additional 10,632 shares during the last quarter. Clark & Stuart Inc purchased a new position in Abbott Laboratories in the 4th quarter worth $2,179,000. Aprio Wealth Management LLC grew its stake in Abbott Laboratories by 46.9% during the 4th quarter. Aprio Wealth Management LLC now owns 5,400 shares of the healthcare product maker’s stock valued at $611,000 after purchasing an additional 1,724 shares during the last quarter. Czech National Bank increased its holdings in shares of Abbott Laboratories by 6.1% in the fourth quarter. Czech National Bank now owns 376,065 shares of the healthcare product maker’s stock valued at $42,537,000 after purchasing an additional 21,630 shares during the period. Finally, ORG Wealth Partners LLC lifted its holdings in shares of Abbott Laboratories by 4.5% during the fourth quarter. ORG Wealth Partners LLC now owns 42,784 shares of the healthcare product maker’s stock worth $4,840,000 after purchasing an additional 1,828 shares during the period. 75.18% of the stock is owned by hedge funds and other institutional investors.

Abbott Laboratories Stock Up 0.2 %

Abbott Laboratories stock traded up $0.24 during trading on Monday, reaching $112.55. The stock had a trading volume of 841,658 shares, compared to its average volume of 4,229,947. Abbott Laboratories has a 52-week low of $99.71 and a 52-week high of $121.64. The business has a 50 day moving average price of $115.33 and a 200 day moving average price of $112.54. The company has a quick ratio of 1.14, a current ratio of 1.60 and a debt-to-equity ratio of 0.32. The stock has a market cap of $195.21 billion, a PE ratio of 34.21, a P/E/G ratio of 2.69 and a beta of 0.73.

Abbott Laboratories (NYSE:ABT) last posted its earnings results on Wednesday, October 16th. The healthcare product maker reported $1.21 EPS for the quarter, beating the consensus estimate of $1.20 by $0.01. The firm had revenue of $10.64 billion for the quarter, compared to analyst estimates of $10.55 billion. Abbott Laboratories had a return on equity of 20.18% and a net margin of 13.99%. Abbott Laboratories’s revenue for the quarter was up 4.9% compared to the same quarter last year. During the same quarter in the prior year, the company posted $1.14 earnings per share. On average, analysts predict that Abbott Laboratories will post 4.67 EPS for the current year.

Abbott Laboratories Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, February 14th. Shareholders of record on Wednesday, January 15th will be issued a dividend of $0.59 per share. This is a positive change from Abbott Laboratories’s previous quarterly dividend of $0.55. The ex-dividend date of this dividend is Wednesday, January 15th. This represents a $2.36 annualized dividend and a dividend yield of 2.10%. Abbott Laboratories’s dividend payout ratio (DPR) is presently 71.73%.

Analyst Ratings Changes

ABT has been the subject of several research reports. UBS Group lifted their price objective on shares of Abbott Laboratories from $143.00 to $146.00 and gave the company a “buy” rating in a research note on Thursday, October 17th. Raymond James reaffirmed a “buy” rating and set a $129.00 price target (up from $122.00) on shares of Abbott Laboratories in a research report on Monday, October 14th. Mizuho raised their target price on Abbott Laboratories from $115.00 to $130.00 and gave the stock a “neutral” rating in a report on Thursday, October 17th. Jefferies Financial Group upped their price objective on Abbott Laboratories from $120.00 to $125.00 and gave the stock a “hold” rating in a research report on Thursday, October 17th. Finally, Oppenheimer began coverage on shares of Abbott Laboratories in a report on Tuesday, October 8th. They set an “outperform” rating and a $130.00 price target on the stock. Four research analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the company’s stock. According to data from MarketBeat, Abbott Laboratories has an average rating of “Moderate Buy” and an average target price of $131.57.

Abbott Laboratories Company Profile

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière’s disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.